美国乳腺癌大分割放疗使用的地理与医师层面差异:一项交叉分类多水平分析
该回顾性研究利用2008至2017年私营雇主保险理赔数据,分析早期乳腺癌患者接受大分割全乳照射(HF-WBI)的地理与医师层面差异。共纳入79,747例(74.0%)接受常规分割全乳照射(CF-WBI)和27,999例(26.0%)接受HF-WBI的患者。HF-WBI使用随时间显著增加,变异主要归因于医师层面(MOR=2.59),核心基础统计区(CBSA)层面变异(MOR=1.55)为所有地理分类中最强。校正变异后,年龄、接受化疗及社区层面因素与HF-WBI使用相关。
要点
- HF-WBI使用从2008至2017年显著增加,但医师层面变异最大(MOR=2.59)。
- CBSA层面变异(MOR=1.55)为地理分类中最强。
- 年龄、化疗及社区因素(距离、教育水平、种族构成)与HF-WBI使用相关。
核心结论
- 研究显示早期乳腺癌患者HF-WBI使用存在地理与医师层面异质性,且与患者及社区特征相关。
- 鉴于医师层面变异,作者认为通过继续医学教育干预可帮助医生更好理解HF-WBI优势并促进其在美国的应用。
- 作者指出医师层面特征对HF-WBI使用的影响值得进一步研究。
研究设计与样本
- 回顾性研究,使用2008至2017年私营雇主保险理赔数据,纳入早期乳腺癌患者。
- 患者按地理层面和放射肿瘤科医师进行聚类,采用贝叶斯交叉分类多水平logistic模型同时评估地理异质性和医师变异。
- 计算组内相关系数(ICC)和中位比值比(MOR)量化不同层面的变异,并识别与接受HF-WBI相关的患者人口学因素。
主要发现
- 共79,747例(74.0%)接受CF-WBI,27,999例(26.0%)接受HF-WBI。
- HF-WBI使用在2008至2017年间显著增加。
- HF-WBI使用的变异主要归因于医师层面变异(MOR=2.59)。
- CBSA层面HF-WBI使用变异(MOR=1.55)为所有地理分类中最强。
- 校正CBSA和放射肿瘤科医师变异后,年龄、接受化疗及社区层面因素(住所至设施距离、社区教育水平、种族构成)与HF-WBI使用相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to assess geographic and physician-level variation for hypofractionated whole-breast irradiation (HF-WBI) use for early-stage breast cancer patients in the United States. We further evaluated the association between HF-WBI use and demographic factors after accounting for these variations. METHODS AND MATERIALS: We performed a retrospective study of early-stage breast cancer patients using private employer-sponsored insurance claims from 2008 to 2017. Patients were clustered according to geographic level and by radiation oncologist. Bayesian cross-classified multilevel logistic models were used to examine the geographic heterogeneity and variation of radiation oncologists simultaneously. Intracluster correlation coefficient (ICC) and median odds ratios (MOR) were calculated to quantify the variation at different levels. We also used the cross-classified model to identify patient demographic factors associated with receiving HF-WBI. RESULTS: The study included 79,747 women (74.0%) who received conventionally fractionated whole-breast irradiation (CF-WBI) and 27,999 women (26.0%) who underwent HF-WBI. HF-WBI adoption increased significantly across time (2008-2017). The variation in HF-WBI utilization was attributed mostly to physician-level variability (MOR = 2.59). The variability of HF-WBI utilization across core-based statistical areas (CBSAs) (MOR = 1.55) was found to be the strongest among all geographic classifications. After accounting for variability in both CBSAs and radiation oncologists, age, receiving chemotherapy, and several community-level factors, including distance from home to facility, community education level, and racial composition, were found to be associated with HF-WBI utilization. CONCLUSION: This study demonstrated geographic and physician-level heterogeneity in the use of HF-WBI among early-stage breast cancer patients. HF-WBI utilization was also found to be associated with patient and community-level characteristics. Given observed physician-level variability, intervention through continuing medical education could help doctors to better understand the advantages of HF-WBI and promote the adoption of HF-WBI in the U.S. Influence of physician-level characteristics on HF-WBI utilization merits further study.
引用
- Sun Y, Saulsberry L, Liao C, et al. Geographic and Physician-Level Variation in the Use of Hypofractionated Radiation Therapy for Breast Cancer in the U.S.: A Cross-Classified Multilevel Analysis. Adv Radiat Oncol. 2024. PMID: 38725638. doi:10.1016/j.adro.2024.101487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。